Your browser doesn't support javascript.
loading
Prospective Assessment of Tumour Burden and Bone Disease in Plasma Cell Dyscrasias Using DW-MRI and Exploratory Bone Biomarkers.
Agarwal, Gaurav; Nador, Guido; Varghese, Sherin; Getu, Hiwot; Palmer, Charlotte; Watson, Edmund; Pereira, Claudio; Sallemi, Germana; Partington, Karen; Patel, Neel; Soundarajan, Rajkumar; Mills, Rebecca; Brouwer, Richard; Maritati, Marina; Shah, Aarti; Peppercorn, Delia; Oppermann, Udo; Edwards, Claire M; Rodgers, Christopher T; Javaid, Muhammad Kassim; Gooding, Sarah; Ramasamy, Karthik.
Afiliación
  • Agarwal G; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK.
  • Nador G; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK.
  • Varghese S; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK.
  • Getu H; Oxford Translational Myeloma Centre, Oxford OX3 7LD, UK.
  • Palmer C; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK.
  • Watson E; Botnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.
  • Pereira C; Botnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.
  • Sallemi G; Botnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.
  • Partington K; Botnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.
  • Patel N; Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
  • Soundarajan R; Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
  • Mills R; Oxford Centre for Magnetic Resonance, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU, UK.
  • Brouwer R; Oxford Centre for Magnetic Resonance, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU, UK.
  • Maritati M; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK.
  • Shah A; Oxford Translational Myeloma Centre, Oxford OX3 7LD, UK.
  • Peppercorn D; Botnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.
  • Oppermann U; Department of Radiology, Hampshire Hospitals NHS Foundation Trust, Hampshire SO22 5DG, UK.
  • Edwards CM; Department of Radiology, Hampshire Hospitals NHS Foundation Trust, Hampshire SO22 5DG, UK.
  • Rodgers CT; Oxford Translational Myeloma Centre, Oxford OX3 7LD, UK.
  • Javaid MK; Botnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.
  • Gooding S; Botnar Research Centre, The Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.
  • Ramasamy K; Nuffield Department of Surgical Sciences (NDS), Oxford OX3 9DU, UK.
Cancers (Basel) ; 15(1)2022 Dec 23.
Article en En | MEDLINE | ID: mdl-36612090
Novel biomarkers for tumour burden and bone disease are required to guide clinical management of plasma cell dyscrasias. Recently, bone turnover markers (BTMs) and Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) have been explored, although their role in the prospective assessment of multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) is unclear. Here, we conducted a pilot observational cohort feasibility study combining serum BTMs and DW-MRI in addition to standard clinical assessment. Fifty-five patients were recruited (14 MGUS, 15 smouldering MM, 14 new MM and 12 relapsed MM) and had DW-MRI and serum biomarkers (P1NP, CTX-1, ALP, DKK1, sclerostin, RANKL:OPG and BCMA) measured at baseline and 6-month follow-up. Serum sclerostin positively correlated with bone mineral density (r = 0.40-0.54). At baseline, serum BCMA correlated with serum paraprotein (r = 0.42) and serum DKK1 correlated with serum free light chains (r = 0.67); the longitudinal change in both biomarkers differed between International Myeloma Working Group (IMWG)-defined responders and non-responders. Myeloma Response Assessment and Diagnosis System (MY-RADS) scoring of serial DW-MRI correlated with conventional IMWG response criteria for measuring longitudinal changes in tumour burden. Overall, our pilot study suggests candidate radiological and serum biomarkers of tumour burden and bone loss in MM/MGUS, which warrant further exploration in larger cohorts to validate the findings and to better understand their clinical utility.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article Pais de publicación: Suiza